Why the study?
Although anti-SSA/Ro antibody positivity is increasingly linked to potentially reversible cardiac conduction block, the clinical features and risk factors for conduction abnormalities in this population remain unclear.
Population
869 adult patients with anti-SSA/Ro antibody positivity (608 training set, 261 internal validation set)
Comparison
Patients with vs without prevalent cardiac conduction block at admission, and low- vs intermediate- vs high-risk score strata
Design
Single-center retrospective risk-stratification model development and internal validation study
Answers are grounded in this paper and cite their sources.
Supports hypothesis-generating risk stratification in anti-SSA/Ro antibody-positive adults; leaves open prospective validation and external generalizability.
Background Anti-SSA/Ro antibody positivity has been increasingly linked to cardiac conduction block (CCB), yet the clinical features and risk factors for conduction abnormalities in this population remain unclear. Unlike degenerative conduction disease, antibody-mediated conduction dysfunction may be reversible at an early stage. This study aimed to identify independent risk factors for prevalent CCB at admission in anti-SSA/Ro antibody-positive patients and to develop an individualized risk-stratification model. Methods In this single-center retrospective study, 869 adult patients with anti-SSA/Ro antibody positivity were enrolled, of whom 174 had CCB at admission, and were randomly divided into a training set ( n = 608) and an internal validation set ( n = 261) at a 7:3 ratio. Lasso regression, univariate and multivariable logistic regression were used for variable selection and model development. Discrimination was assessed by the area under the receiver operating characteristic curve (AUC), calibration by the Hosmer-Lemeshow test, and clinical utility by decision curve analysis. Based on the regression coefficients of the multivariable logistic regression model, the coefficients were simplified into an simplified risk score, and patients were stratified into low-, intermediate- and high-risk groups by the tertiles of the total score in the training set, missing values imputed separately within each set and all model parameters derived from the training set. Results Twelve variables were selected by Lasso regression, and multivariable logistic regression identified Gender (OR = 2.12, 95% CI 1.41–3.21, P < 0.001), Age (per 1-year increase: OR = 1.03, 95% CI 1.02–1.05, P < 0.001) and Heart rate (per 1-beat/min increase: OR = 0.99, 95% CI 0.97–0.99, P = 0.045) as independent predictors of prevalent CCB at admission. The AUC was 0.68 (95% CI 0.63–0.74) and 0.70 (95% CI 0.62–0.78) in the training and internal validation sets, respectively, and the corresponding Hosmer-Lemeshow P values were 0.9676 and 0.7584.In the internal validation set, the calibration intercept was −0.04 (95% CI −0.35 to 0.28) and the calibration slope 1.12 (95% CI 0.61 to 1.63). The odds of CCB increased stepwise across the low-, intermediate- and high-risk strata in both sets (intermediate risk: OR 2.54 and 2.80; high risk: OR 4.73 and 6.56, respectively). Conclusion Female Gender, Age and Heart rate were independent predictors of prevalent CCB at admission in anti-SSA/Ro antibody-positive patients. A risk score based on these three predictors stratified patients into low-, intermediate- and high-risk groups, with a stepwise increase in the odds of CCB that was reproduced in the internal validation set. Discrimination was nevertheless modest and, pending external validation, the score should serve as an adjunctive tool for preliminary risk stratification rather than for individual prediction or diagnosis.
No takes yet. Share an insight, caveat, or question.
Gu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: